🇺🇸 FDA
Patent

US 8628782

Deletion of the beta 20-21 loop in HIV gp120 exposes the CD4 binding site for improved antibody binding and antibody induction

granted A61KA61K2039/5258A61K2039/545

Quick answer

US patent 8628782 (Deletion of the beta 20-21 loop in HIV gp120 exposes the CD4 binding site for improved antibody binding and antibody induction) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jan 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jan 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/5258, A61K2039/545, A61K2039/55505, A61K2039/55561